Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Alexion (ALXN) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Alexion (ALXN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Sweta Killa headshot

5 Most-Loved S&P 500 Stocks on Wall Street

by Sweta Killa

Given the bullishness and record-high market, we have screened for five S&P 500 stocks that are most loved by the brokerage firms.

Celgene (CELG) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sanghamitra Saha headshot

Pharma Sector Tops in October: Best ETFs & Stocks

by Sanghamitra Saha

Pharma sector wins in October, making these ETFs and stocks winners.

Sweta Jaiswal, FRM headshot

Biotech ETFs in Focus on Impressive Q3 Earnings Results

by Sweta Jaiswal, FRM

Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q3 earnings results recently.

Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (ALXN) Outperforming Other Medical Stocks This Year?

The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG

ALXN or CBM: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ALXN vs. CBM: Which Stock Is the Better Value Option?

Sanghamitra Saha headshot

Try Rising P/E Investing With 5 Top-Ranked Stocks

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More

by Zacks Equity Research

Key highlights include earnings updates, collaboration deals, and regulatory and pipeline updates.

Sweta Killa headshot

Healthcare ETFs Win in October: Here's Why

by Sweta Killa

The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.

Here is Why Growth Investors Should Buy Alexion (ALXN) Now

by Zacks Equity Research

Alexion (ALXN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More

by Zacks Equity Research

Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.

The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals

Company News For Oct 24, 2019

by Zacks Equity Research

Companies In The News Are: ALXN,ANTM,TMO,BSX

Alexion (ALXN) Beats on Q3 Earnings, Lifts 2019 Guidance

by Zacks Equity Research

Alexion (ALXN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.

Sweta Killa headshot

Biotech ETFs Surge on a Flurry of Positive News

by Sweta Killa

The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.

Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates

by Zacks Equity Research

Key highlights of the past week include acquisition news, and regulatory and pipeline updates.

Alexion Pharmaceuticals (ALXN) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Alexion (ALXN) delivered earnings and revenue surprises of 12.05% and 1.87%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More

by Zacks Equity Research

Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.

What's in Store for IDEXX Laboratories' (IDXX) Q3 Earnings?

by Zacks Equity Research

Growth in Rapid Assays and Veterinary Software revenues is expected to get reflected in IDEXX's (IDXX) third-quarter results.

What's in the Cards for Sarepta (SRPT) This Earnings Season?

by Zacks Equity Research

Sarepta Therapeutics' (SRPT) third-quarter results are expected to reflect the impact of strong demand for Exondys 51. Regulatory update related to golodirsen is what investors are expected be focused on.

Is Walgreens Boots (WBA) Likely to Disappoint in Q4 Earnings?

by Zacks Equity Research

Persistent de-emphasizing of tobacco is hurting growth, which should get reflected in the upcoming quarterly results of Walgreens Boots Alliance (WBA).

Alexion Gets FDA Approval for Label Expansion of Ultomiris

by Zacks Equity Research

Alexion (ALXN) obtains FDA approval for the label expansion of Ultomiris for the treatment of ultra-rare disease, aHUS.

Will Soliris Aid Growth for Alexion (ALXN) in Q3 Earnings?

by Zacks Equity Research

During Alexion's (ALXN) third-quarter earnings call, investor focus will be on the sales performance of its blockbuster drug Soliris along with the sales figure of Ultomiris, Strensiq and Kanuma.